It looks like Pfizer might be anticipating some very bad news.
They quietly added a language warning that “Unfavorable Pre-Clinical, Clinical Or Safety Data” may impact business.
Now, Pfizer – which just forecast $54 billion in Covid-related sales in 2022, appears to be anticipating some bad news, as evidenced by several redline changes in their Q4 earnings releases.
As Rubicon Capital’s Kelly Brown notes on Twitter, the changes center aroundÂ disclosures of unfavorable safety data.
For example, in Q4 they added: “or further information regarding the quality of pre-clinical, clinical or safety data, including by audit or inspection.”
"…challenges related to public confidence or awareness of our COVID-19 vaccine or Paxlovid, including challenges driven by misinformation, access, CONCERNS ABOUT CLINICAL DATA INTEGRITY and prescriber and pharmacy education;"
(all-caps are mine) pic.twitter.com/bAKH4iqiKs
— Kelly Brown (@rubiconcapital_) February 8, 2022
The Palmieri Report is a Pro-America News Outlet founded by Jacob Palmieri. The Palmieri Report is dedicated to giving people the truth so that they can form their own informed political opinions.Â
Follow us on social media:
Listen to our Daily News Podcast!